Key Takeaways Altimmune's pemvidutide showed MASH resolution without worsening fibrosis in a phase IIb study.ALT's dual glucagon and GLP-1 pathways aim to target liver fat, inflammation and weight loss togetherALT plans a 1,800-patient phase III MASH trial in 2026 with FDA-aligned endpoints for approvalAltimmune (ALT) is advancing pemvidutide as a differentiated approach to serious liver diseases where effective options remain limited.The key question for investors is whether pemvidutide’s dual-pathway biol ...

Taysha Gene Therapies (NasdaqGS:TSHA) Q4 2025 Earnings call March 19, 2026 08:30 AM ET Company ParticipantsHayleigh Collins - Senior Director of Corporate Communications and Investor RelationsKamran Alam - CFOSean Nolan - CEOSukumar Nagendran - President and Head of R and DTazeen Ahmad - Managing Director of US Equity ResearchConference Call ParticipantsBiren Amin - Managing Director and Senior Research AnalystChris Raymond - Senior Biotech Research AnalystGil Blum - Senior AnalystJack Allen - AnalystKriste ...

Breakthrough Therapy Designation granted to nomlabofusp for the treatment of adults and children with FA based on FDA’s review of available clinical data from open label studyContinued alignment with FDA to consider the use of skin FXN to support BLA submission seeking accelerated approval following recent START pilot program meetingTopline open label study data to support BLA submission expected in Q2 2026Plan to initiate screening in global Phase 3 confirmatory study in Q2 2026, with dosing of first patie ...

Core Insights - Larimar Therapeutics (LRMR) shares increased by 55% over the past month following significant regulatory updates regarding nomlabofusp, its leading pipeline asset [1] Regulatory Updates - The FDA granted breakthrough therapy designation (BTD) to nomlabofusp for treating Friedreich's ataxia (FA), a rare neurodegenerative disorder [2] - BTD is intended to expedite the development and review of therapies for severe diseases where preliminary evidence suggests substantial improvements over existing treatments [3] Clinical Data - Preliminary data from an ongoing open-label study indicated increases in skin FXN levels comparable to asymptomatic carriers of the FA gene mutation [4] - The study demonstrated consistent improvement across four key clinical outcomes after one year of treatment, including mFARS, FARS-ADL, 9-HPT, and MFIS [4] - These findings suggest that nomlabofusp may slow disease progression compared to the worsening typically seen in untreated FA patients [5] Future Plans - Larimar received positive feedback from the FDA regarding a potential regulatory filing for nomlabofusp, with skin FXN levels considered as a novel surrogate endpoint [6] - Top-line data from the ongoing study is expected in Q2 2026, with plans to submit a regulatory filing to the FDA in June 2026 if results are positive [7] - A confirmatory late-stage study is planned, with the first patient dosing anticipated in mid-2026 [10][12] Market Context - The recent stock rally reflects improved investor confidence in Larimar's pipeline, which relies solely on nomlabofusp for growth [8] - The limited treatment landscape for FA, with only one approved drug (Skyclarys by Biogen), enhances the opportunity for nomlabofusp [9] - Year-to-date, Larimar's shares have risen by 37%, contrasting with the industry's breakeven growth [9]

Core Insights - Altimmune, Inc. is advancing its lead candidate pemvidutide, which has received FDA Breakthrough Therapy Designation for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) [3][15] - The company plans to initiate a Phase 3 trial for pemvidutide in MASH in 2026, with topline data from the RECLAIM Phase 2 trial in Alcohol Use Disorder (AUD) expected in the third quarter of 2026 [1][3] Financial Performance - As of December 31, 2025, Altimmune reported cash, cash equivalents, and short-term investments totaling $274 million, a 107% increase from $132 million at the end of 2024 [11] - The company completed a registered direct offering in January 2026, raising $75 million, and an additional $8 million through its At-the-Market facility [11] - For the fourth quarter of 2025, the net loss was $27.4 million, or $0.27 per share, compared to a net loss of $23.2 million, or $0.33 per share, in the same period in 2024 [21] Clinical Development - The IMPACT Phase 2b trial of pemvidutide in MASH reported positive 48-week data, showing statistically significant improvements in key non-invasive markers of fibrosis and inflammation [6] - The RECLAIM trial for AUD is evaluating pemvidutide's safety and efficacy against placebo in approximately 100 patients over a 24-week period, with enrollment completed ahead of schedule in November 2025 [7][11] - The RESTORE Phase 2 trial of pemvidutide in Alcohol-Associated Liver Disease (ALD) is ongoing, with approximately 100 patients enrolled [11] Leadership and Strategy - Jerry Durso has been appointed as the Chief Executive Officer, bringing over 30 years of experience in life sciences and corporate strategy [11] - The company is focused on strengthening its financial and operational foundation to support the successful execution of its clinical programs [3]

Core Insights - Larimar Therapeutics has received Breakthrough Therapy status from the FDA, aimed at expediting the development of drugs that may enhance outcomes for serious conditions [2] - The company plans to submit a Biologics License Application (BLA) in 2026 for its protein replacement therapy, Nomlabofusp, targeting frataxin deficiency in Friedreich's ataxia [3] - Larimar's stock has shown significant upward momentum, trading 13.6% above its 20-day simple moving average and 23.01% higher over the past 12 months [4] FDA Breakthrough Therapy Status - The Breakthrough Therapy designation is intended to accelerate the development of drugs that could improve treatment outcomes compared to existing therapies [2] - Larimar's strategy includes using skin frataxin levels as a potential surrogate endpoint in its BLA for accelerated approval [2] Stock Performance - Larimar's shares increased by 31.67% to $3.70, with key resistance at $4.00 and support at $3.50 [6] - The stock is currently positioned closer to its 52-week highs, indicating a favorable long-term trend [4] Technical Indicators - The Relative Strength Index (RSI) is at 33.78, indicating neutral territory, while the MACD shows a value of -0.1482, suggesting bearish pressure [5] - The combination of a neutral RSI and bearish MACD indicates mixed momentum for the stock [5]

Core Insights - Larimar Therapeutics has received Breakthrough Therapy Designation from the FDA for nomlabofusp, a therapy aimed at treating Friedreich's ataxia, indicating the potential for significant improvement over existing treatments [1][3][5] FDA Designation and Clinical Data - The Breakthrough Therapy Designation was based on preliminary clinical data from an ongoing open label study, which showed promising results in both adult and pediatric patients with Friedreich's ataxia [2][7] - The FDA has acknowledged the use of skin FXN as a novel surrogate endpoint to support the planned Biologics License Application (BLA) submission, which is targeted for June 2026 [1][13] Clinical Outcomes and Efficacy - Preliminary data from the open label study indicated increases in skin FXN levels and consistent improvements across four key clinical outcomes: modified Friedreich Ataxia Rating Scale (mFARS) score, FARS-Activities of Daily Living (ADL), 9 Hole Peg Test (9-HPT), and Modified Fatigue Impact Scale (MFIS) after one year of treatment [4][5] - These findings suggest that nomlabofusp may modify the disease course of Friedreich's ataxia, contrasting with worsening observed in a reference group from the FACOMS natural history study [4][5] Future Plans and Milestones - The company plans to submit the BLA seeking accelerated approval in June 2026, with a U.S. launch targeted for the first half of 2027, contingent on approval [7][14] - A global confirmatory Phase 3 study is set to be initiated, with screening expected to begin in Q2 2026 and dosing of the first patient anticipated by mid-2026 [8][14] Company Overview - Larimar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, with nomlabofusp as its lead compound for Friedreich's ataxia [11]

FDA Designation - The FDA granted Breakthrough Therapy Designation for subcutaneous Rybrevant Faspro as a monotherapy for adults with advanced head and neck squamous cell carcinoma [1] - The designation is for patients with recurrent or metastatic cancer that is HPV-unrelated after progression on platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [2] - Rybrevant Faspro is also approved for multiple settings in locally advanced or metastatic non-small cell lung cancer and is being evaluated in additional solid tumors, including colorectal cancer [2] Clinical Studies - The Breakthrough Therapy Designation is supported by data from the open-label Phase 1b/2 OrigAMI-4 study, which showed promising clinical activity with rapid and durable responses in a heavily pretreated patient population [3] - Subcutaneous amivantamab is being further evaluated in the ongoing Phase 3 OrigAMI-5 study, assessing its combination with Merck's Keytruda and carboplatin versus 5-fluorouracil plus pembrolizumab and platinum-based chemotherapy for HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma [4] New Dosing Schedule - The FDA approved a new, simplified monthly dosing schedule for Rybrevant Faspro in combination with oral Lazcluze for the first-line treatment of EGFR-mutated advanced non-small cell lung cancer [5] Contract Extension - Trellus Health plc extended its contract with Johnson & Johnson's Health Care Systems unit for six months to continue providing Trellus Elevate for patients with moderate to severely active inflammatory bowel disease [6] - The extension was influenced by the achievement of engagement and satisfaction metrics during the initial pilot phase [6]

Core Insights - Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) has received Breakthrough Therapy Designation from the U.S. FDA for treating advanced head and neck squamous cell carcinoma in patients who have progressed after platinum-based chemotherapy and PD-1/PD-L1 inhibitors [1][2] Group 1: FDA Designation and Clinical Data - The Breakthrough Therapy Designation is based on clinical data showing rapid and durable responses in heavily pretreated patients, indicating a significant need for new therapies in this area [1][2] - The designation expands the application of RYBREVANT FASPRO™ beyond its current approval for non-small cell lung cancer [1][2] - The clinical activity supporting this designation comes from the Phase 1b/2 OrigAMI-4 study, which demonstrated promising results in a challenging patient population [1][2] Group 2: Treatment Mechanism and Patient Impact - RYBREVANT FASPRO™ targets both epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET) pathways, which are overexpressed in HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma [1][2] - The dual targeting approach has shown meaningful clinical benefits in lung cancer, with the aim of improving patient outcomes in head and neck cancer as well [1][2] Group 3: Ongoing Studies and Future Directions - RYBREVANT FASPRO™ is currently being evaluated in the ongoing Phase 3 OrigAMI-5 study, which compares its efficacy in combination with pembrolizumab and carboplatin against standard treatments [1][2] - The FDA's Breakthrough Therapy Designation aims to expedite the development and regulatory review process for therapies that show substantial improvement over existing options [1][2] Group 4: Background on Head and Neck Cancer - Head and neck squamous cell carcinoma accounts for over 90% of head and neck cancer cases and approximately 4.5% of all cancers globally, with a significant portion being HPV-negative, which is associated with poorer prognosis [1][2] - Despite advancements in treatment, many patients progress to advanced, recurrent, or metastatic disease, highlighting the urgent need for new therapeutic options [1][2]

Core Viewpoint - Sanofi's rilzabrutinib has received breakthrough therapy designation from the FDA and orphan drug designation in Japan for treating warm autoimmune hemolytic anemia (wAIHA), highlighting the urgent need for effective treatments for this rare autoimmune disorder [1][3][4]. Group 1: Designations and Studies - The FDA's breakthrough therapy designation aims to expedite the development of medicines for serious conditions, indicating rilzabrutinib may show substantial improvement over existing treatments [3]. - Rilzabrutinib is currently being evaluated in the LUMINA 2 phase 2b study and the new LUMINA 3 phase 3 study, which compares rilzabrutinib with placebo for wAIHA patients [2]. - There are no approved treatments specifically targeting the underlying causes of wAIHA, which can lead to severe health complications [2]. Group 2: Rilzabrutinib Overview - Rilzabrutinib is a novel oral, reversible Bruton's tyrosine kinase (BTK) inhibitor, already approved for immune thrombocytopenia (ITP) in the US, EU, and UAE, and under review in Japan [4][8]. - The drug addresses immune system dysregulation through multi-immune modulation, making it a potential treatment for various rare diseases [7][8]. - Rilzabrutinib has received multiple regulatory designations, including orphan drug status for autoimmune hemolytic anemia and other rare diseases [5][9]. Group 3: About wAIHA - Warm autoimmune hemolytic anemia is a rare and potentially life-threatening condition, affecting 4 to 24 individuals per 100,000 in the US and EU, and 3 to 10 per million in Japan [6]. - Symptoms include fatigue, dizziness, and serious complications like thromboembolism, emphasizing the need for effective treatments [6]. Group 4: Company Overview - Sanofi is an R&D-driven biopharma company focused on improving lives through innovative medicines and vaccines, with a commitment to addressing urgent healthcare challenges [10].